|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/454 | |
| A61K 31/4985 | |||
| A61K 31/7056 | |||
| A61K 45/06 | |||
| A61P 31/22 |
| (11) | Patento numeris | 3318258 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17189252.4 |
| Europos patento paraiškos padavimo data | 2014-03-14 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-05-09 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-05-13 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 201361783437 P | 2013-03-14 | US |
| (72) |
BERNSTEIN, Barry M., US
DUTTA, Sandeep, US
LIU, Wei, US
PODSADECKI, Thomas J., US
CAMPBELL, Andrew L., US
MENON, Rajeev M., US
LIN, Chih-Wei, US
WANG, Tianli, US
AWNI, Walid M., US
MENSING, Sven, DE
|
| (73) |
AbbVie Inc.,
1 North Waukegan Road, North Chicago, IL 60064,
US
|
| (54) | COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS |
| COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS |